Patents by Inventor Benoit Vanhollebeke

Benoit Vanhollebeke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT SIGNALING AGONIST MOLECULES
    Publication number: 20240092848
    Abstract: Therapeutic agents are capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling. The agents do not activate Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders that include neurovascular dysfunction.
    Type: Application
    Filed: October 6, 2023
    Publication date: March 21, 2024
    Inventor: Benoit VANHOLLEBEKE
  • WNT SIGNALING AGONIST MOLECULES
    Publication number: 20230399369
    Abstract: Therapeutic agents are capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling. The agents do not activate Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders that include neurovascular dysfunction.
    Type: Application
    Filed: April 20, 2023
    Publication date: December 14, 2023
    Inventor: Benoit VANHOLLEBEKE
  • Wnt7 variants capable of activating g-protein coupled receptor (Gpr)124/Reck/frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling
    Patent number: 11840557
    Abstract: Novel therapeutic agents, particularly those capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, while not activating Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders including neurovascular dysfunction.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 12, 2023
    Assignee: UNIVERSITÉ LIBRE DE BRUXELLES
    Inventor: Benoit Vanhollebeke
  • WNT SIGNALING AGONIST MOLECULES
    Publication number: 20230212240
    Abstract: The present application relates to novel therapeutic agents, particularly to agents capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, wherein said agents do not activate Frizzled/LRP -mediated Wnt signaling in the absence of RECK and/or GPR124. The present agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders comprising neurovascular dysfunction.
    Type: Application
    Filed: September 14, 2022
    Publication date: July 6, 2023
    Inventor: Benoit VANHOLLEBEKE
  • WNT SIGNALING AGONIST MOLECULES
    Publication number: 20210309704
    Abstract: Novel therapeutic agents, particularly those capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, while not activating Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders including neurovascular dysfunction.
    Type: Application
    Filed: March 22, 2019
    Publication date: October 7, 2021
    Inventor: Benoit VanHollebeke
  • APOLIPOPROTEIN L-I VARIANTS AND THEIR USE
    Publication number: 20150011735
    Abstract: The present invention is related to an isolated human Apolipoprotein L-I corresponding to this wild type human Apolipoprotein sequence modified by a deletion at its C-terminal end.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 8, 2015
    Inventors: Etienne PAYS, Laurence LECORDIER, Benoit VANHOLLEBEKE
  • PHARMACEUTICAL COMPOSITION COMPRISING APOLIPOPROTEINS FOR THE TREATMENT OF HUMAN DISEASES
    Publication number: 20090162333
    Abstract: A pharmaceutical composition has an adequate pharmaceutical carrier or diluent and an element selected from a pharmaceutical composition having an adequate pharmaceutical carrier or diluent and an element selected from: —apolipoprotein apoL-III; —a pharmaceutically active fragment of this apolipoprotein apoL-III; —a nucleotide sequence encoding this apolipoprotein apoL-III or the fragment; —a vector having the nucleotide sequence; —a cell transformed by the nucleotide sequence or the vector; —an inhibitor or activator directed against the apolipoprotein apoL-III, its fragment or its nucleotide sequence, —an anti-inhibitor or anti-activator directed against the inhibitor or activator or its encoding nucleotide sequence.
    Type: Application
    Filed: May 25, 2007
    Publication date: June 25, 2009
    Applicant: Universite Libre de Bruxelles
    Inventors: Etienne Pays, Benoit Vanhollebeke